Psoriasis is a chronic inflammatory disease with a multifactorial origin that appears in
patients with genetic predisposition and is induced by environmental factors, and …

Background Secukinumab, an anti‐interleukin‐17A monoclonal antibody, has demonstrated
rapid and sustained efficacy in phase 3 psoriasis trials. Objectives To examine whether …

Background The prevalence of psoriasis is increasing among older people. Elderly patients
with psoriasis represent a challenge for dermatologists owing to multiple comorbidities …

Psoriasis (PsO) is a common, systemic, chronic, inflammatory disease characterized by key
clinical symptoms, including itching, pain, and scaling. PsO is associated with a high …

Objective To report the 5‐year efficacy and safety of secukinumab in the treatment of
patients with psoriatic arthritis (PsA) in the FUTURE 1 study (NCT 01392326). Methods …

Objective Secukinumab provided sustained efficacy, low radiographic progression and
consistent safety over 52 weeks in patients with psoriatic arthritis (PsA) in the FUTURE 5 …

Erythrodermic psoriasis (EP) is a dermatological emergency and its treatment with
secukinumab is still controversial. Furthermore, no data exist regarding the prognostic value …

Psoriasis is a common, chronic, immune‐mediated disease occurring more frequently in
association with comorbid metabolic disorders. The management of patients with multiple …

Background Secukinumab has demonstrated high, sustained efficacy in psoriasis to 52
weeks on a fixed-interval regimen. Objective We sought to compare a retreatment-as …

Methods: We reviewed the treatment efficacy of all patients with moderate-to-severe
psoriasis who used secukinumab as monotherapy and did not reach Psoriasis Area Severity …